DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea
· Delayed Price · Currency is KRW 5,760.00
-80.00 (-1.37%)
At close: Dec 5, 2025
DongKoo Bio & Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 235,784 | 248,515 | 215,064 | 194,496 | 155,131 | 139,216 | Upgrade
|
| Other Revenue | 2,604 | 760.23 | 622 | 491.86 | 17.86 | - | Upgrade
|
| Revenue | 238,388 | 249,275 | 215,686 | 194,988 | 155,149 | 139,216 | Upgrade
|
| Revenue Growth (YoY) | -6.04% | 15.57% | 10.62% | 25.68% | 11.45% | 37.67% | Upgrade
|
| Cost of Revenue | 94,906 | 97,396 | 83,610 | 77,128 | 62,812 | 58,673 | Upgrade
|
| Gross Profit | 143,482 | 151,879 | 132,076 | 117,860 | 92,337 | 80,543 | Upgrade
|
| Selling, General & Admin | 126,443 | 129,706 | 105,675 | 91,394 | 72,852 | 60,016 | Upgrade
|
| Research & Development | 9,799 | 8,380 | 10,752 | 8,258 | 10,114 | 10,751 | Upgrade
|
| Amortization of Goodwill & Intangibles | 185.74 | 182.86 | 144.88 | 124.77 | 109.81 | 84.57 | Upgrade
|
| Other Operating Expenses | 289.9 | 375.81 | 203.67 | 273.54 | 282.42 | 249.5 | Upgrade
|
| Operating Expenses | 137,512 | 139,188 | 117,460 | 101,023 | 84,198 | 72,932 | Upgrade
|
| Operating Income | 5,970 | 12,691 | 14,616 | 16,836 | 8,139 | 7,611 | Upgrade
|
| Interest Expense | -3,588 | -2,894 | -1,760 | -1,039 | -415.63 | -430.83 | Upgrade
|
| Interest & Investment Income | 209.45 | 224.42 | 310.5 | 179.43 | 50.88 | 77.57 | Upgrade
|
| Currency Exchange Gain (Loss) | 216.9 | 93.19 | 20.79 | 30.37 | 101.41 | -61.72 | Upgrade
|
| Other Non Operating Income (Expenses) | -321.64 | 505.2 | 287.04 | 956.37 | 4,102 | 473.76 | Upgrade
|
| EBT Excluding Unusual Items | 2,487 | 10,619 | 13,474 | 16,963 | 11,978 | 7,670 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1,729 | -10,584 | 2,881 | 4,501 | 1,827 | 7,453 | Upgrade
|
| Gain (Loss) on Sale of Assets | 3,432 | 7,114 | 401.74 | 136.72 | 2,258 | -57.93 | Upgrade
|
| Asset Writedown | -4,180 | -3,331 | -2,016 | -13,685 | -4,728 | -4,765 | Upgrade
|
| Pretax Income | 9.94 | 3,819 | 14,741 | 7,916 | 11,333 | 10,300 | Upgrade
|
| Income Tax Expense | -695.07 | 1,828 | 2,932 | 1,302 | 2,007 | 1,160 | Upgrade
|
| Earnings From Continuing Operations | 705.02 | 1,991 | 11,808 | 6,614 | 9,327 | 9,140 | Upgrade
|
| Minority Interest in Earnings | 65.3 | 44.78 | 3.17 | - | - | - | Upgrade
|
| Net Income | 770.31 | 2,036 | 11,812 | 6,614 | 9,327 | 9,140 | Upgrade
|
| Net Income to Common | 770.31 | 2,036 | 11,812 | 6,614 | 9,327 | 9,140 | Upgrade
|
| Net Income Growth | -94.98% | -82.77% | 78.59% | -29.09% | 2.04% | -16.48% | Upgrade
|
| Shares Outstanding (Basic) | 27 | 27 | 28 | 28 | 28 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 28 | 27 | 28 | 28 | 28 | 28 | Upgrade
|
| Shares Change (YoY) | 0.89% | -1.13% | -0.48% | -1.78% | -0.12% | 25.96% | Upgrade
|
| EPS (Basic) | 28.48 | 74.54 | 427.63 | 238.29 | 330.05 | 323.08 | Upgrade
|
| EPS (Diluted) | 27.83 | 74.54 | 427.63 | 238.29 | 330.05 | 323.08 | Upgrade
|
| EPS Growth | -95.02% | -82.57% | 79.46% | -27.80% | 2.16% | -31.98% | Upgrade
|
| Free Cash Flow | -18,577 | -4,522 | -10,260 | 11,841 | 13,637 | 2,221 | Upgrade
|
| Free Cash Flow Per Share | -671.22 | -165.59 | -371.44 | 426.63 | 482.57 | 78.50 | Upgrade
|
| Gross Margin | 60.19% | 60.93% | 61.23% | 60.45% | 59.51% | 57.86% | Upgrade
|
| Operating Margin | 2.50% | 5.09% | 6.78% | 8.63% | 5.25% | 5.47% | Upgrade
|
| Profit Margin | 0.32% | 0.82% | 5.48% | 3.39% | 6.01% | 6.57% | Upgrade
|
| Free Cash Flow Margin | -7.79% | -1.81% | -4.76% | 6.07% | 8.79% | 1.59% | Upgrade
|
| EBITDA | 14,844 | 19,964 | 20,644 | 22,469 | 13,193 | 12,117 | Upgrade
|
| EBITDA Margin | 6.23% | 8.01% | 9.57% | 11.52% | 8.50% | 8.70% | Upgrade
|
| D&A For EBITDA | 8,874 | 7,274 | 6,028 | 5,632 | 5,054 | 4,506 | Upgrade
|
| EBIT | 5,970 | 12,691 | 14,616 | 16,836 | 8,139 | 7,611 | Upgrade
|
| EBIT Margin | 2.50% | 5.09% | 6.78% | 8.63% | 5.25% | 5.47% | Upgrade
|
| Effective Tax Rate | - | 47.87% | 19.89% | 16.44% | 17.71% | 11.26% | Upgrade
|
| Advertising Expenses | - | 2,848 | 1,595 | 1,630 | 1,971 | 3,013 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.